Display options
Cite
Bhutani G, Gupta MC. Emerging therapies for the treatment of osteoporosis. J Midlife Health. 2013;4(3):147-52doi: 10.4103/0976-7800.118991.
Bhutani, G., & Gupta, M. C. (2013). Emerging therapies for the treatment of osteoporosis. Journal of mid-life health, 4(3), 147-52. https://doi.org/10.4103/0976-7800.118991
Bhutani, Garima, and Gupta, Mahesh Chander. "Emerging therapies for the treatment of osteoporosis." Journal of mid-life health vol. 4,3 (2013): 147-52. doi: https://doi.org/10.4103/0976-7800.118991
Bhutani G, Gupta MC. Emerging therapies for the treatment of osteoporosis. J Midlife Health. 2013 Jul;4(3):147-52. doi: 10.4103/0976-7800.118991. PMID: 24672186; PMCID: PMC3952405.
Copy Download .nbib Format: NLM
Share it on

J Midlife Health. 2013 Jul;4(3):147-52. doi: 10.4103/0976-7800.118991.

Emerging therapies for the treatment of osteoporosis.

Journal of mid-life health

Garima Bhutani, Mahesh Chander Gupta

Affiliations

  1. Department of Pharmacology, Pt. B.D. Sharma Post Graduate Institute of Medical Sciences, Rohtak, Haryana, India.

PMID: 24672186 PMCID: PMC3952405 DOI: 10.4103/0976-7800.118991

Abstract

Osteoporosis is a chronic disease of the osseous system characterized by decreased bone strength and increased fracture risk. It is due to an imbalance in the dynamic ongoing processes of bone formation and bone resorption. Currently available osteoporosis therapies like bisphosphonates, selective estrogen receptor modulators (SERMs), and denosumab are anti-resorptive agents. Parathyroid hormone analogs like teriparatide are the only anabolic agents currently approved for osteoporosis treatment. The side-effects and limited efficacy of the presently available therapies has encouraged extensive research into the pathophysiology of the disease and newer drug targets for its treatment. The novel anti-resorptive agents being developed are newer SERMs, osteoprotegerin, c-src (cellular-sarcoma) kinase inhibitors, αVβ3 integrin antagonists, cathepsin K inhibitors, chloride channel inhibitors, and nitrates. Upcoming anabolic agents include calcilytics, antibodies against sclerostin and Dickkopf-1, statins, matrix extracellular phosphoglycoprotein fragments activin inhibitiors, and endo-cannabinoid agonists. Many of these new drugs are still in development. This article provides an insight into the emerging drugs for the treatment of osteoporosis.

Keywords: Anabolic agent; anti-resorptive agent; bone formation; bone resorption; osteoporosis

References

  1. Cochrane Database Syst Rev. 2008 Jan 23;(1):CD004523 - PubMed
  2. Bone. 2012 May;50(5):1135-40 - PubMed
  3. Drugs Aging. 2011 Jan 1;28(1):63-82 - PubMed
  4. J Bone Miner Res. 2010 Mar;25(3):463-71 - PubMed
  5. Eur J Clin Invest. 2009 Apr;39(4):296-303 - PubMed
  6. Eur J Pharmacol. 2011 Oct 1;668(1-2):331-6 - PubMed
  7. J Clin Endocrinol Metab. 2005 Apr;90(4):2022-8 - PubMed
  8. J Bone Miner Res. 2011 Jan;26(1):19-26 - PubMed
  9. Am J Pathol. 2004 May;164(5):1537-45 - PubMed
  10. Endocr Rev. 2012 Oct;33(5):747-83 - PubMed
  11. J Bone Miner Res. 2004 Mar;19(3):455-62 - PubMed
  12. J Pathol. 2004 Apr;202(4):503-10 - PubMed
  13. Maturitas. 2010 Apr;65(4):301-7 - PubMed
  14. World Health Organ Tech Rep Ser. 1994;843:1-129 - PubMed
  15. J Bone Miner Res. 2007 Oct;22(10):1534-47 - PubMed
  16. Bone. 2010 Feb;46(2):534-42 - PubMed
  17. J Exp Pharmacol. 2010 Aug 27;2:121-34 - PubMed
  18. Menopause. 2009 Mar-Apr;16(2):413-21 - PubMed
  19. Dev Biol. 2004 Aug 1;272(1):134-44 - PubMed
  20. Osteoporos Int. 2012 Mar;23(3):1091-101 - PubMed
  21. Endocrinology. 2004 May;145(5):2148-56 - PubMed
  22. Osteoporos Int. 2006 Feb;17(2):225-30 - PubMed
  23. Osteoporos Int. 2006 Oct;17(10):1532-8 - PubMed
  24. J Bone Miner Res. 2010 May;25(5):937-47 - PubMed
  25. IDrugs. 2008 Nov;11(11):827-40 - PubMed
  26. Drug News Perspect. 2005 Oct;18(8):489-95 - PubMed
  27. Cell Metab. 2009 Aug;10(2):139-47 - PubMed
  28. J Bone Miner Res. 2004 Sep;19(9):1512-7 - PubMed
  29. J Bone Miner Res. 2009 Jul;24(7):1234-46 - PubMed
  30. J Bone Miner Res. 2006 Nov;21(11):1811-7 - PubMed
  31. Chem Biol. 2000 Mar;7(3):225-35 - PubMed
  32. Climacteric. 2013 Jun;16(3):338-46 - PubMed
  33. J Clin Endocrinol Metab. 2010 Jan;95(1):151-8 - PubMed
  34. J Biol Chem. 2003 Jan 17;278(3):1998-2007 - PubMed
  35. J Bone Miner Res. 2001 Feb;16(2):348-60 - PubMed
  36. Immunol Rev. 2005 Dec;208:106-25 - PubMed
  37. J Bone Miner Res. 2009 Apr;24(4):578-88 - PubMed
  38. J Bone Miner Res. 2011 Nov;26(11):2610-21 - PubMed
  39. Bone. 2010 Jan;46(1):64-71 - PubMed
  40. Expert Opin Investig Drugs. 2009 May;18(5):585-600 - PubMed
  41. Science. 1996 Aug 30;273(5279):1236-8 - PubMed
  42. Bone. 2010 Apr;46(4):1011-5 - PubMed

Publication Types